Page 18 - Lon Gsk News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lon gsk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lon Gsk Today - Breaking & Trending Today
GSK and Sanofi look to catch up in vaccine race with booster doses Approval may come a year later after their competitors, but the pair reckon there is a need for their candidate GlaxoSmithKline PLC (LON:GSK) and Sanofi are planning to join the vaccine race well after their competitors as they pin their hopes on the need for boosters. The pair have received lukewarm market reaction despite posting positive mid-stage trial results for their COVID-19 vaccine. The FTSE 100 pharma company was flat on Monday as investors are likely waiting for phase 3 numbers before popping the champagne open. The jab, which has encountered some hiccups along the way, showed 95% to 100% seroconversion (immunisation after the development of antibodies) following two doses. ....
17 May 2021 | 16:39pm StockMarketWire.com - On an up and down (and up) day the FTSE 100 ended up erasing earlier losses to trade only slightly lower at 7,032.85. The move, which came as most of the UK eased coronavirus restrictions, came despite a weak start on Wall Street with the S&P 500 down 0.5% to 4,151.47 by 4.30pm UK time. Technical products and services provider Diploma rallied 6.8% to £29.38, having upgraded its annual outlook thanks to a boost from acquisitions, particularly WCW, and improved underlying trading. Diploma s annual revenue was now expected to be slightly better than 40% ahead of the 2020 financial year, with an increase in its margin towards 19%. ....
28 April 2021 | 13:36pm StockMarketWire.com - GlaxoSmithKline recorded £7.4 billion of sales in the first quarter, an 18 per cent drop from the same period in 2020. Turnover was impacted due to Covid-19 disruption but the company s management insists the long-term strategy remains on course. During the quarter, turnover from pharmaceuticals products dropped 12 per cent to £3.9 billion. Turnover from vaccines was also impacted, reflecting government privatisation initiatives. Turnover of £1.2 billion was generated, which was down 32 per cent from the previous year. Despite earnings per share slumping by 32 per cent to 21.5p, total group operating margins were 22.8 per cent. This allowed the pharmaceutical giant to generated net cash flow of £331 million from its operations, versus a outflow of £3 million. ....
Liberum expects a spike in revenue after short-term headwinds this and next year GlaxoSmithKline PLC’s (LON:GSK) spinoff is expected to deliver above-sector sales growth contrary to market scepticism, analysts at Liberum said. The FTSE 100 group plans to split into two companies in 2022, consumer health and biopharma, and the outlook for the latter is regarded as the benchmark for the success of the spinoff. The City broker looked at the key product and franchise areas that will define GSK’s biopharma business over the next decade. Strong organic growth in oncology and vaccines will deliver steady growth from this year until 2030, analysts said, which will allow margin leverage and an earnings profile that is not properly reflected in the valuation. ....